# Eli Lilly Launches LillyPod DGX SuperPOD for Drug Discovery

> Eli Lilly has inaugurated LillyPod, which it describes as the world's first NVIDIA DGX SuperPOD built with the new B300 systems, dedicated to pharmaceutical research. The supercomputer is aimed at accelerating drug discovery, genomics, and clinical development, and it was built in partnership with Nvidia at a scale meant for industrial pharma workloads. The move signals how seriously large drugmakers now take in-house AI compute. Rather than renting capacity, Lilly is standing up dedicated infrastructure to run the large models involved in finding and testing candidate molecules. If AI can meaningfully shorten the years and billions it takes to bring a drug to market, owning the compute becomes a competitive advantage. It is also a notable win for Nvidia, whose most advanced systems are increasingly landing in the hands of customers well outside traditional tech.

_Section: [Daily AI Updates](https://www.wortins.com/daily-ai) · Source: Drug Target Review · Published Friday, August 28, 2026_

## Wortins' read

Eli Lilly has inaugurated LillyPod, which it describes as the world's first NVIDIA DGX SuperPOD built with the new B300 systems, dedicated to pharmaceutical research. The supercomputer is aimed at accelerating drug discovery, genomics, and clinical development, and it was built in partnership with Nvidia at a scale meant for industrial pharma workloads. The move signals how seriously large drugmakers now take in-house AI compute. Rather than renting capacity, Lilly is standing up dedicated infrastructure to run the large models involved in finding and testing candidate molecules. If AI can meaningfully shorten the years and billions it takes to bring a drug to market, owning the compute becomes a competitive advantage. It is also a notable win for Nvidia, whose most advanced systems are increasingly landing in the hands of customers well outside traditional tech.

## Source

[Read the full story at Drug Target Review](https://www.drugtargetreview.com/ai-in-drug-discovery-predictions-for-2026/1865962.article)

## Related coverage

- [Emerald AI Raises $150 Million Series A at $1.05 Billion Valuation](https://www.wortins.com/story/emerald-ai-raises-150-million-series-a-at-1-05-billion-valua-2071899e) — [Business Wire](https://www.businesswire.com/news/home/20260825127649/en/Emerald-AI-Raises-$150-Million-Series-A-at-$1.05-Billion-Valuation-to-Scale-Power-Flexible-AI-Data-Centers)
- [SoftBank Plans Record $6.3 Billion Retail Bond Sale to Fund OpenAI Investment](https://www.wortins.com/story/softbank-plans-record-6-3-billion-retail-bond-sale-to-fund-o-dbc93b82) — [Bloomberg](https://www.bloomberg.com/news/videos/2026-08-20/bloomberg-tech-8-20-2026-video)
- [Checking In on AI and the Big Five](https://www.wortins.com/story/checking-in-on-ai-and-the-big-five-8f54332c) — [Stratechery](https://stratechery.com/2025/checking-in-on-ai-and-the-big-five/)
- [Stripe Acquires OpenRouter for $7B+](https://www.wortins.com/story/stripe-acquires-openrouter-for-7b-2abe2a10) — [TechCrunch](https://techcrunch.com/2026/08/16/stripe-will-reportedly-acquire-ai-gateway-startup-openrouter-for-7b/)
- [Anthropic Signs $45 Billion Compute Deal with British Infrastructure Firm Nscale](https://www.wortins.com/story/anthropic-signs-45-billion-compute-deal-with-british-infrast-9d89144c) — [TechCrunch](https://techcrunch.com/2026/08/26/anthropic-continues-compute-gobbling-streak-in-45-billion-deal-with-nscale/)
- [Fundraisly](https://www.wortins.com/story/fundraisly-75fbe87d) — [Futurepedia](https://futurepedia.io/)

---

_Curated and written by [Wortins](https://www.wortins.com) — The daily AI briefing. Every story links to its original source; the "Wortins read" on each is our own original analysis. [About Wortins & our editorial approach](https://www.wortins.com/about)._